| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PVR; PVS; HVED; NECL5; TAGE4; Necl-5 |
| Entrez GeneID | 5817 |
| clone | 6D2D6 |
| WB Predicted band size | 45.3kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD155 (AA: 21-343) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于CD155抗体的关键文献概览：
---
1. **文献名称**: *Structural basis for CD96 immune receptor recognition of nectin-like protein-5. CD155*
**作者**: Stengel KF, et al. (2012)
**摘要**: 通过X射线晶体学解析了CD96受体与CD155结合的分子结构，揭示了抗体靶向CD155表位的关键结合域，为设计阻断性抗体提供了结构基础。
2. **文献名称**: *CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms*
**作者**: Müller TR, et al. (2020)
**摘要**: 研究显示，抗CD155抗体通过阻断肿瘤细胞与TIGIT/CD96等免疫检查点的相互作用，增强T细胞杀伤活性，并在神经母细胞瘤模型中抑制肿瘤生长。
3. **文献名称**: *Anti-poliovirus receptor (PVR/CD155) antibodies as potential cancer therapeutics*
**作者**: Iguchi-Manaka A, et al. (2008)
**摘要**: 早期研究证明，抗CD155单克隆抗体通过阻断PVR介导的免疫抑制信号通路，在小鼠模型中显著抑制黑色素瘤转移并延长生存期。
---
**领域覆盖**：结构生物学(Stengel, 2012)、肿瘤免疫治疗(Müller, 2020)、抗体机制研究(Iguchi-Manaka, 2008)。如需扩展至病毒感染或更近期研究，可补充相关文献。
CD155. also known as poliovirus receptor (PVR) or necl-5. is a cell surface glycoprotein belonging to the immunoglobulin superfamily. Initially identified as the receptor for poliovirus, it plays dual roles in cellular adhesion and immune regulation. Structurally, CD155 interacts with ligands like DNAM-1 (activating) and TIGIT or CD96 (inhibitory), modulating NK and T-cell responses. In cancer, CD155 is frequently overexpressed in tumors, contributing to immune evasion by engaging inhibitory receptors on immune cells, thereby suppressing antitumor activity. This makes it a promising target for immunotherapy.
CD155 antibodies are designed to block these immunosuppressive interactions or directly promote antibody-dependent cellular cytotoxicity (ADCC). Preclinical studies show that anti-CD155 antibodies can enhance immune cell activation, inhibit tumor growth, and synergize with checkpoint inhibitors (e.g., anti-PD-1). Some bispecific antibodies targeting CD155 and other immune checkpoints are under exploration. Challenges include understanding context-dependent roles (pro- vs anti-tumor) and managing potential on-target toxicity due to CD155’s expression in healthy tissues like neurons and placenta. Current research focuses on optimizing antibody specificity and evaluating clinical efficacy in trials, positioning CD155 as an emerging immune-oncology target.
×
